These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30761450)

  • 1. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.
    Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J
    Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    Li WY; Zhao TT; Xu HM; Wang ZN; Xu YY; Han Y; Song YX; Wu JH; Xu H; Yin SC; Liu XY; Miao ZF
    BMC Cancer; 2019 Feb; 19(1):145. PubMed ID: 30760227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
    Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T
    Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
    Wang C; Lu X; Lyu Z; Bi N; Wang L
    Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
    Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
    Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.
    Iuchi T; Shingyoji M; Itakura M; Yokoi S; Moriya Y; Tamura H; Yoshida Y; Ashinuma H; Kawasaki K; Hasegawa Y; Sakaida T; Iizasa T
    Int J Clin Oncol; 2015 Aug; 20(4):674-9. PubMed ID: 25336382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
    Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
    Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 12. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.
    Sekine A; Kato T; Hagiwara E; Shinohara T; Komagata T; Iwasawa T; Satoh H; Tamura K; Kasamatsu T; Hayashihara K; Saito T; Takahashi H; Ogura T
    Lung Cancer; 2012 Jul; 77(1):64-9. PubMed ID: 22335887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
    Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
    Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang H; Cai W; Wang Y; Liao M; Tian S
    Int J Clin Oncol; 2019 Jun; 24(6):649-659. PubMed ID: 30835006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y; Wang Q; Han ZG; Shan L
    Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
    Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
    J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
    Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
    Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.